4150-30-5

Basic information

• Product Name: 5-ANDROSTENE-3B,16A,17B-TRIOL
• Synonyms: 5-ANDROSTENE-3B,16A,17B-TRIOL;(8R,9S,10R,13S,14S)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,16,17-triol;5-Androstenetriol;5-Androstene-3,16,17-triol;5-Androstene-3B,16ALPHA,17B-triol;5-androstene-3beta,16alpha,17beta-trihydroxy-5-androstene;3β,16α,17β-Trihydroxy-5-androstene;Androst-5-ene-3β,16α,17β-triol
• CAS NO: 4150-30-5
• Molecular Formula: C₁₉H₃₀O₃
• Molecular Weight: 306.4397
• Mol File: 4150-30-5.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 449.8°Cat760mmHg
• Flash Point: 205°C
• Appearance: /
• Density: 1.19g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.587
• CAS DataBase Reference: 5-ANDROSTENE-3B,16A,17B-TRIOL(CAS DataBase Reference)
• NIST Chemistry Reference: 5-ANDROSTENE-3B,16A,17B-TRIOL(4150-30-5)
• EPA Substance Registry System: 5-ANDROSTENE-3B,16A,17B-TRIOL(4150-30-5)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 4150-30-5(Hazardous Substances Data)

Usage

InChI:InChI=1/C19H30O3/c1-18-7-5-12(20)9-11(18)3-4-13-14(18)6-8-19(2)15(13)10-16(21)17(19)22/h3,12-17,20-22H,4-10H2,1-2H3/t12-,13+,14-,15-,16+,17-,18-,19-/m0/s1

Upstream product

• 979-62-4 3β-acetoxy-5α,6β-dichloroandrostan-17-one 
• 17975-95-0 5α,6β-dichloroandrost-16-en-3β,17-diol diacetate 
• 6767-49-3 methyl-(16α,17β-dihydroxy-androsten-(5)-yl-(3β))-ether 
• 110248-17-4 17β-hydroxy-3β-methoxy-androsten-(5)-one-(16) 
• 10587-75-4 17-oxoandrost-5-ene-3β,16α-diyl diacetate 
• 94618-85-6 benzoyloxy-16α benzoyloxy-3β androstene-5 one-17 
• 94703-18-1 3β,16α,17β-triacetoxy-androst-5-ene 
• 53-43-0 dehydroepiandrosterone 

Relevant articles and documents

DRUGS AND USES

The invention relates to methods to treat specified clinical disorders such as hyperglycemia, type 2 diabetes, arthritis and multiple sclerosis. The invention also provides methods to identify and characterize drugs, which are characterized in part by eliciting a variable biologic or therapeutic effect on a biomolecule at one time and relative normalization of the biomolecule at another time point. Compounds include 17α-ethynylandrost-5-ene-3β,7β, 17β-triol or androst-5-ene-3β,4β, 16α, 17β-tetrol, which can be used as reference standards to facilitate assessing and characterizing such candidate drugs.

The in vivo metabolism of 16-alpha-hydroxydehydroisoandrosterone in man.

-